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factor kinase involved in cell survival
Chiara Naro1,2,y, Federica Barbagallo1,2,y, Paolo Chieffi3, Cyril F. Bourgeois4,
Maria Paola Paronetto2,5 and Claudio Sette1,2,*
1Department of Biomedicine and Prevention, University of Rome ‘Tor Vergata’, Rome, Italy, 2Laboratories of
Neuroembryology and of Cellular and Molecular Neurobiology, Fondazione Santa Lucia IRCCS, 00143 Rome,
Italy, 3Department of Psychology, II University of Naples, Caserta, Italy, 4Department of Functional Genomics
and Cancer, Institut de Genetique et de Biologie Moleculaire et Cellulaire, F-67400, INSERM U964,
F-67400 Illkirch, France and 5Department of Health Sciences, University of Rome Foro Italico, Rome, Italy
Received August 8, 2013; Revised November 14, 2013; Accepted November 25, 2013
ABSTRACT
NEK2 is a serine/threonine kinase that promotes
centrosome splitting and ensures correct chromo-
some segregation during the G2/M phase of the cell
cycle, through phosphorylation of specific sub-
strates. Aberrant expression and activity of NEK2
in cancer cells lead to dysregulation of the centro-
some cycle and aneuploidy. Thus, a tight regulation
of NEK2 function is needed during cell cycle pro-
gression. In this study, we found that NEK2 localizes
in the nucleus of cancer cells derived from several
tissues. In particular, NEK2 co-localizes in splicing
speckles with SRSF1 and SRSF2. Moreover, NEK2
interacts with several splicing factors and phos-
phorylates some of them, including the oncogenic
SRSF1 protein. Overexpression of NEK2 induces
phosphorylation of endogenous SR proteins and
affects the splicing activity of SRSF1 toward
reporter minigenes and endogenous targets, inde-
pendently of SRPK1. Conversely, knockdown of
NEK2, like that of SRSF1, induces expression of
pro-apoptotic variants from SRSF1-target genes
and sensitizes cells to apoptosis. Our results
identify NEK2 as a novel splicing factor kinase and
suggest that part of its oncogenic activity may be
ascribed to its ability to modulate alternative
splicing, a key step in gene expression regulation
that is frequently altered in cancer cells.
INTRODUCTION
NEK2 is a member of the NIMA-related family of serine/
threonine protein kinases, which share structural relation-
ships and the involvement in cell cycle regulation (1).
NEK2 displays constitutive catalytic activity and phos-
phorylates proteins involved in centrosome duplication
and cell cycle regulation (2). Consistently, NEK2 binds
to microtubules and is enriched in the centrosome,
where it contributes to centrosome splitting during the
G2/M phase of the cell cycle (2). Upregulation of NEK2
in human cells causes premature splitting of this organelle
(3), whereas overexpression of a NEK2 kinase-dead
mutant induces centrosome abnormalities and aneuploidy
(4). Hence, a tight regulation of NEK2 abundance and
activity is essential to ensure correct centrosome duplica-
tion and timely progression of the cell cycle.
Similar to other kinases involved in spindle assembly or
duplication (5), overexpression of NEK2 was reported
in several neoplastic diseases, such as preinvasive and
invasive breast carcinomas (6), lung adenocarcinomas
(7), testicular seminomas (8) and diffuse large B cell
lymphomas (9). More recently, NEK2 expression has
been proposed as a strong predictor for drug resistance
and poor prognosis in human cancer, suggesting that it
might represent a key therapeutic target (10). In line with
this hypothesis, pharmacologic or genetic interference
with NEK2 activity strongly reduced proliferation and
invasiveness of cancer cells (10–12). Mechanistically, the
oncogenic activity of NEK2 has been mainly linked to its
ability to regulate centrosome duplication (3,6,13), whose
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aberrant ampliﬁcation frequently leads to aneuploidy and
neoplastic transformation (6). Overexpression of NEK2
in non-transformed breast epithelial cells was shown
to induce centrosome overduplication (6), and increased
expression of endogenous NEK2 caused centrosome
ampliﬁcation in breast cancer lesions expressing the onco-
genic K-RAS(G12D) mutant protein (13). Furthermore,
NEK2-dependent phosphorylation was required for
proper localization at the kinetochores of HEC1, a
protein involved in faithful chromosome segregation
(14). These observations strongly suggest that NEK2-
dependent centrosome ampliﬁcation and aneuploidy can
favour neoplastic transformation.
We previously reported that increased expression of
NEK2 in human testicular seminomas correlated with
its accumulation in the nucleus (8). This observation sug-
gested that nuclear functions of NEK2 might also contrib-
ute to its role in cancer cells. Herein, we have studied
in further detail the nuclear localization and function of
this kinase. We found that nuclear localization of NEK2
occurs in cancer cells derived from several tissues. NEK2
localizes to splicing speckles and phosphorylates the onco-
genic splicing factor SRSF1. Moreover, we found that
NEK2 regulates SRSF1 activity and alternative splicing
(AS) of SRSF1 target genes similarly to the SR protein
kinase SRPK1. In particular, NEK2 promotes anti-
apoptotic splice variants and knockdown of its expression
enhanced apoptosis. Our results uncover a novel function
for NEK2 in splicing regulation and suggest that phos-
phorylation of splicing factors and modulation of AS
might contribute to its oncogenic activity.
MATERIALS AND METHODS
Immunohistochemistry and immunoﬂuorescence analysis
Cancer patient’s tissues (14 cases of cryopreserved tissue
from seminoma, breast, lung, prostate, cervix and colon
cancer) were obtained from the National Cancer Institute
‘G. Pascale’ Ethical Committee approval was given in all
instances. Five-micrometer sections were processed for
immunohistochemistry with antibodies against NEK2
(Abgent) as described (8). Immunoﬂuorescence was per-
formed as described (8,15) using the following primary
antibodies (1:500): rabbit anti-NEK2 (Abgent), mouse
anti-SRSF1, anti-SRSF2 (Santa Cruz Biotechnology)
and rabbit anti-cleaved CASPASE 3 (Sigma Aldrich).
Confocal analyses were performed using a Leica
confocal microscope as described (16). Images in
Figure 6D, S2 and S5 were taken using a Leica inverted
microscope as described (8). Images were saved as TIFF
ﬁles and Photoshop (Adobe) was used for composing
panels.
Cell culture, transfections and treatment
TCam-2 cells were grown in RPMI 1640 (Lonza),
HEK293T, HeLa, MCF7, PC-3 cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (Sigma Aldrich),
all supplemented with 10% FBS, gentamycin, penicillin
and streptomycin. Transfection with the indicated expres-
sion vectors was performed using Lipofectamine 2000
(Invitrogen) according to manufacturer’s instructions.
After 24 h, cells were harvested for protein and RNA
analyses. For RNA interference, cells were transfected
with siRNAs (Sigma-Aldrich) using Lipofectamine
RNAiMAX (Invitrogen) according to manufacturer’s
instructions and harvested 48 h later for protein and
RNA analyses. Sequences for SRPK1 siRNAs were pre-
viously described (17). NEK2, SRSF1 siRNAs and
scrambled siRNA sequences are listed in Supplementary
Table S1. For apoptosis, HeLa cells were treated for 24 h
with the indicated doses of cisplatin or starved for 8 h in
Earle’s balanced salt solution (Sigma).
Protein extracts and western blot analysis
Total cellular extracts and cellular fractionations were
processed and analysed by western blot as described
(15,18) using the following primary antibodies (1:1000):
rabbit anti-NEK2 R31 (generously provided by Prof.
A.M. Fry); mouse anti-GFP, anti-MYC, anti-SRSF1,
anti-SRSF3, rabbit anti-SAM68 and goat anti-lamin B
(Santa Cruz Biotechnology); rabbit anti-ACTIN, mouse
anti-FLAG, anti-hnRNPA1, anti-hnRNPC1/C2 and
anti-TUBULIN (Sigma-Aldrich); mouse anti-hnRNPF/
H (Abcam); mouse anti-SR proteins (1H4) (Invitrogen),
mouse anti-SRPK1 (BD Pharmingen); rabbit anti-AKT
(Novus Biologicals); rabbit anti-pAKT Ser 473 and anti-
PARP1 (Cell Signaling).
In vitro kinase assay
Glutathione S-transferase (GST)-fusion proteins were ex-
pressed in Escherichia coli cells (strain BL21-DE3) and
puriﬁed as previously described (19). (His)6-tagged
proteins were expressed in Sf9 cells using a baculovirus
system and puriﬁed on a TALON afﬁnity resin
(CLONETECH), as described (20). In vitro kinase assays
were performed as described (21), using puriﬁed NEK2
active protein (Millipore).
GST–pull-down and co-immunoprecipitation assays
Nuclear extracts were incubated with GST or GST-
NEK2A(271–445) adsorbed on glutathione-agarose
beads; bound proteins were eluted and analyzed as
described (19). For co-immunoprecipitation, nuclear
extracts or total extracts from HEK293T cells, transfected
with the indicated vectors, were incubated with mouse
anti-FLAG or mouse anti-IgG antibodies adsorbed on
Dynabeads protein A (Invitrogen) and immunocomplexes
were eluted and analysed as described (15).
Extraction of RNA, reverse transcriptase-polymerase
chain reaction and real-time polymerase chain reaction
analysis
RNA was extracted using TRIzol reagent (Invitrogen) ac-
cording to the manufacturer’s instructions. After digestion
with RNase-free DNase (Roche), 1 mg of total RNA was
retrotranscribed using M-MLV reverse transcriptase
(Promega), used as template for polymerase chain
reaction (PCR; GoTaq, Promega) and reactions were
analysed on agarose or acrylamide gels. Real-time quan-
titative PCRs (qPCR) were performed using LightCycler
Nucleic Acids Research, 2014, Vol. 42, No. 5 3219
Downloaded from https://academic.oup.com/nar/article-abstract/42/5/3218/1059216
by Service Commun de Documentation user
on 06 February 2018
480 SYBR Green I Master and the LightCycler 480
System (Roche), according to the manufacturer’s instruc-
tions. Control reactions omitting M-MLV reverse tran-
scriptase were also carried out. All primers used are
listed in the Supplementary Table S1.
Statistical analysis
Statistical analysis was performed by the Student t-test as
described in the ﬁgure legends.
RESULTS
NEK2 is enriched in the nucleus of cancer cells
NEK2 is enriched in the nucleus of human testicular
seminoma cells (8). Nuclear localization of this kinase
was also recently observed in myeloma cells and shown
to correlate with poor prognosis (10). To investigate
whether other cancer cells that overexpress NEK2 share
this nuclear localization, we performed immunohisto-
chemistry analysis of tissue specimens derived from
cancer patients. Using a previously validated antibody
(8), we observed that NEK2 staining was concentrated in
the nucleus of breast and lung cancer cells (Figure 1A). In
colon, prostate and cervix cancer cells, although it was also
detected in the cytoplasm, NEK2 staining was enriched in
nucleus (Figure 1A). Confocal immunoﬂuorescence
analyses of NEK2 localization in cell lines derived from
breast cancer (MCF7; Figure 1B), seminoma (TCam-2),
prostate cancer (PC-3), colon carcinoma (Caco-2) and
cervix cancer (HeLa) (Supplementary Figure S1) suggest
that nuclear localization of NEK2 is a common feature
of human cancer cells.
NEK2 is expressed as three alternative splice variants,
named NEK2A, B and C (Supplementary Figure S2A)
(22). NEK2A and B differ in the C-termini because an al-
ternative polyadenylation signal in intron 7 is used in
NEK2B, thus preventing inclusion of the last exon 8 (2).
Notably, exon 8 encodes for protein degradation motifs in
NEK2A, which mediate its degradation in mitosis (23).
NEK2C is identical to NEK2A with the exception of a
small internal deletion of 8 amino acids (missing residues
371–378), due to usage of a downstream splice acceptor site
in exon 8 (22). Although the biochemical features of
NEK2C are undistinguishable from those of NEK2A,
deletion of this sequence creates a nuclear localization
signal that promotes NEK2C accumulation in the
nucleus (22). To investigate which splice variant was preva-
lently expressed in cancer cell lines, we performed reverse
transcriptase-polymerase chain reaction (RT-PCR)
analyses using variant-speciﬁc primers (Supplementary
Figure S2A). NEK2A and B were readily detected in all
cell lines analysed, whereas NEK2C was barely detectable
(Supplementary Figure S2B), suggesting that its expression
is unlikely to account for the nuclear localization of NEK2
in cancer cells.
Previous results indicated that a substantial fraction of
NEK2A localizes in the nucleus when the protein is
overexpressed (22). In line with this report, we observed
that overexpression of NEK2A was sufﬁcient to allow its
accumulation in the nucleus of HeLa cells, with a local-
ization pattern that closely resembled that of NEK2C
A Breast cancer
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Figure 1. NEK2 localizes in the nucleus of cancer cells. (A) Immunohistochemistry of NEK2 in testicular seminomas, breast, prostate, lung and
cervix cancer specimens (scale bar=25 mm). (B and C) Confocal immunoﬂuorescence analysis of MCF7 cells stained with anti-NEK2 (red) antibody
and Hoechst (blue) (B, scale bar=10 mm) or with anti-NEK2 (green), anti-SRSF1 (red, upper panel) or anti-SRSF2 (red, lower panel) (C, scale
bar=5 mm). White arrows indicate co-localization in speckles.
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(Supplementary Figure S2C), whereas NEK2B remained
mainly cytoplasmic (Supplementary Figure S2C). These
results suggest that upregulation of NEK2A is likely
responsible for the nuclear localization of NEK2 in
cancer cells.
NEK2 localizes in nuclear splicing speckles and
co-fractionates with splicing factors
We found that NEK2 accumulated in nuclear granules
of variable size and irregular shape (Figure 1B,
Supplementary Figure S1), which resembled the splicing
speckles, the interchromatin regions enriched in splicing
factors (24). Confocal immunoﬂuorescence analysis in
MCF7 cells conﬁrmed that NEK2 co-localizes in the
nuclear speckles with SRSF1 and SRSF2 (Figure 1C),
two serine/arginine-rich (SR) proteins commonly used as
markers of these structures (24). We next used subcellular
fractionation experiments to conﬁrm the association of
NEK2 with splicing factors. By using this technique, it
was documented that splicing factors accumulate in the
nuclear matrix-attached insoluble fraction (18). Analyses
of cytosolic (S), nuclear soluble (NS), and nuclear matrix-
attached insoluble (NI) fractions conﬁrmed that splicing
factors were enriched in the NI fraction isolated from
MCF7, PC-3 and TCam-2 cells (Figure 2A). In addition,
we observed that NEK2 was also enriched in both the NS
and the NI fraction in all cell lines tested (Figure 2A). The
molecular weight of this band corresponded to that of
NEK2A and C. A faster migrating band corresponding
to the molecular weight of NEK2B was instead detected
in the cytosolic fraction.
NEK2 interacts with substrates and activators through
the carboxyl terminal regulatory region (residues 273–445,
Supplementary Figure S2A) (2). Thus, we used puriﬁed
GST-NEK2A(271–445) fusion protein as bait in afﬁnity
chromatography of nuclear extracts isolated from
MCF7 and PC-3 cells. GST-NEK2A(271–445) selectively
associated with some splicing regulators, as SRSF1,
hnRNPA1, hnRNPF and SAM68, but not others, as
SRSF3 and hnRNPC1/C2 (Figure 2B). These results
suggest that NEK2 interacts with speciﬁc splicing factors
in the cell nucleus.
NEK2 is a splicing factor kinase
Next, we set out to determine whether splicing factors were
substrates for NEK2. We focused on SR proteins because
their splicing activity is ﬁnely tuned by phosphorylation
(25,26). As ﬁrst step, we determined whether SRSF1 and
SRSF7 were directly phosphorylated by NEK2. Kinase
assays using puriﬁed full-length HIS- or GST-fusion
proteins of these splicing factors showed that puriﬁed
NEK2 efﬁciently phosphorylates SRSF1 and SRSF7
in vitro (Figure 3A). We focused the rest of our study on
SRSF1 because it was more efﬁciently phosphorylated by
NEK2. Furthermore, this splicing factor is a bona ﬁde
oncogene (27) and it is upregulated in several human
cancers, including breast and prostate carcinomas, where
it modulates cancer-relevant AS events (28,29).
First, we investigated whether the interaction between
NEK2 and SRSF1 also occurred in live cells. We found
that GFP-NEK2C (Figure 3B) and GFP-NEK2A
(Supplementary Figure S3A) were efﬁciently co-
immunoprecipitated with FLAG-SRSF1 in HEK293T
cells, whereas the cytosolic GFP-NEK2B was not
(Supplementary Figure S2C and S3B). Next, to verify the
ability of NEK2 to phosphorylate SRSF1 in live cells, we
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Figure 2. NEK2 associates with splicing factors. (A) Cytosolic (C),
nuclear soluble (NS) and nuclear insoluble matrix-associated (NI) frac-
tions of MCF7, PC-3, TCam-2 cells were analysed by western blot
using antibodies for NEK2 and indicated splicing factors. LAMIN B
and TUBULIN were evaluated as nuclear matrix and cytosolic
markers. (B) Western blot analysis for the indicated splicing factors
in pull-down assays of MCF7 and PC-3 nuclear extracts with GST-
NEK2A(271–445) fusion protein and GST (as negative control).
Coomassie staining shows the puriﬁed GST and GST-NEK2A(271–
445) fusion protein (lower panels).
Nucleic Acids Research, 2014, Vol. 42, No. 5 3221
Downloaded from https://academic.oup.com/nar/article-abstract/42/5/3218/1059216
by Service Commun de Documentation user
on 06 February 2018
co-expressed wild-type or kinase-dead GFP-NEK2C with
GFP-SRSF1. When expressed alone, GFP-SRSF1 yielded
two bands, with the faster migrating band being more
abundant, indicating that the bulk of the protein is
hypophosphorylated (Figure 3C). Expression of wild-type
NEK2C increased the amount of the higher molecular
weight band of SRSF1, suggesting its hyperphosphory-
lation, whereas kinase-dead NEK2C was ineffective
(Figure 3C). A similar result was obtained with NEK2A
(Supplementary Figure S3C), indicating that both NEK2
splice variants can phosphorylate SRSF1 in live cells.
NEK2 behaves as an SR protein kinase in live cells
Having established that NEK2 phosphorylates SRSF1, we
asked whether it behaves as an SR protein kinase (SRPK).
For these studies, we focused on NEK2C, which was
chosen for its almost exclusive localization in the nucleus
(22). Overexpression of NEK2C induced a pattern of SR
protein phosphorylation similar to that elicited by
SRPK1, a prototypical SRPK (26), leading to phosphor-
ylation of SRSF6 (SRp55), SRSF5 (SRp40) and SRSF2/
SRSF9 (SRp30) (Figure 4A).
Next, we tested whether NEK2 functionally regulates
the activity of SR proteins. Previous reports demonstrated
that overexpression of SRPK1 modulates splicing of the
E1A reporter minigene (17), a commonly used splicing
target that contains several 50 and 30 alternative splice
sites (ss) (Figure 4B). As expected (17), we observed that
increasing the expression of SRPK1 in HeLa cells caused
a dose-dependent switch from the 13S to the 9S 50 splice
site of the E1A minigene (Figure 4C). Remarkably,
upregulation of NEK2C caused a similar switch in E1A
splicing. This effect required the kinase activity of NEK2,
as the kinase-dead mutant had no effect (Figure 4C).
Thus, NEK2 displays features of an SRPK in live cells.
NEK2 expression modulates SRSF1-dependent BCL-X
splicing
Phosphorylation of SR proteins regulates their splicing
activity (25,26). Thus, we asked whether NEK2 could
modulate the AS of an endogenous target of SRSF1,
such as the BCL-X gene (15,30). Selection of two alterna-
tive 50 ss in exon 2 of BCL-X leads to the production of two
splice variants: the anti-apoptotic BCL-XL and the pro-
apoptotic BCL-XS (31). SRSF1 promotes selection of the
proximal 50 ss leading to expression of BCL-XL (15,30). By
performing real-time qPCR using exon junction-speciﬁc
primers for BCL-XL and BCL-XS (Figure 5A), we found
that overexpression of NEK2C in HeLa cells increased
the BCL-XL/BCL-XS ratio to a similar extent as over-
expression of SRSF1 (Figure 5B). Importantly, this effect
was not due to activation of SRPK1. While knockdown of
SRPK1 promoted the pro-apoptotic BCL-XS variant,
indicating that SRPK1 also modulates this AS event,
NEK2C was still capable to enhance splicing of the anti-
apoptotic BCL-XL variant in SRPK1-depleted cells as
observed in control cells (Figure 5C).
To determine whether NEK2 expression affected the
ability of SRSF1 to modulate BCL-X AS, we used a
minigene that recapitulates the splicing of the endogenous
gene (32). We found that knockdown of NEK2 in
HEK293T cells slightly enhanced splicing of the pro-
apoptotic BCL-XS variant (Figure 5D). Moreover, while
transfection of suboptimal amounts of SRSF1 efﬁciently
promoted splicing of the anti-apoptotic BCL-XL variant
in control cells (si-SCR), this effect was partially impaired
when NEK2 was silenced (Figure 5D). Importantly,
similar effects were also observed when SRPK1 was
knocked down, even though silencing of both NEK2
and SRPK1 did not exert additive effect on SRSF1-
induced BCL-X splicing (Figure 5D).
NEK2 is involved in the regulation of apoptosis
Next, we sought out to determine whether AS of known
endogenous targets of SRSF1 was affected by the
knockdown of NEK2 in HeLa cells. We examined the
splicing pattern of SRSF1 target transcripts from three
genes with roles in cancer and for which AS variants
have been characterized: BCL-X, MKNK2 and BIN1
(15,27,30,33). For comparison, we also knocked down
SRSF1 and SRPK1 in parallel experiments (Figure 6A
and B). Transient knockdown of NEK2 in HeLa cells
resulted in decreased ratio of BCL-XL/BCL-XS and
MNK2b/MNK2a, and induces skipping of exon 12A in
BIN1 mRNA variants, without affecting SRSF1 expres-
sion. All the splicing changes exerted by NEK2 depletion
favoured pro-apoptotic splice variants and were recapitul-
ated by knockdown of either SRSF1 or SRPK1, although
to different extent for the three genes (Figure 6A and B).
Moreover, as observed for BCL-XL, overexpression
of either NEK2C or SRSF1 promoted splicing of
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Figure 3. NEK2 phosphorylates splicing factors. (A) Puriﬁed NEK2
was incubated with puriﬁed GST (as negative control), SRSF1-
(His)6, SRSF1-GST or SRSF7-(His)6 proteins and g-[
32P]ATP.
Phosphorylation levels were detected by autoradiography (asterisk
indicates autophosphorylated NEK2). Coomassie staining shows the
puriﬁed proteins (lower panel). (B) Western blot analysis with anti-
GFP and anti-FLAG antibodies of the immunoprecipitation assay per-
formed with control mouse IgG or anti-FLAG antibody of nuclear
extracts of HEK293T expressing FLAG-SRSF1 and GFP-NEK2C.
(C) Western blot analysis using anti-GFP antibody of HEK293T cells
transfected with GFP-SRSF1, wild-type NEK2C (WT) or kinase-dead
NEK2C (KD). ACTIN was used as loading control.
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anti-apoptoticMKNK2 andBIN1 variants (Supplementary
Figure 4A). These results indicate that NEK2 contributes
to the regulation of SRSF1 splicing activity.
Because NEK2 knockdown induced expression of pro-
apoptotic splice variants, we asked whether it also plays a
role in cell viability. In line with its effect on AS, depletion
of the endogenous NEK2 in HeLa cells signiﬁcantly
increased the basal level of apoptosis, as monitored
by cleavage of PARP1 (Figure 6C) and CASPASE 3
(Figure 6D), and enhanced the apoptotic response of cells
to stress, such as treatment with cisplatin (Figure 6C and
D) or starvation (Supplementary Figure 4B and C). These
results suggest that the effect of NEK2 on AS events
regulated by SRSF1 is physiologically relevant.
DISCUSSION
NEK2 is a centrosomal kinase involved in centrosome
duplication in mitosis that is frequently upregulated in
human cancers (2). Recent evidence suggests that
nuclear localization of NEK2 is a predictor for drug re-
sistance and a marker of poor prognosis in patients (10).
Nevertheless, the speciﬁc nuclear functions of NEK2 are
still completely obscure. The present study indicates that
NEK2 acts as a regulator of AS events by modulating
SRSF1 activity, thus uncovering a previously unknown
nuclear function for this oncogenic kinase.
NEK2 overexpression has been extensively described in
several types of tumours (2,6–10). Its oncogenic activity
has been primarily ascribed to the ability to induce aneu-
ploidy by perturbing centrosome duplication and its
segregation dynamics (2). However, it was recently
demonstrated that in testicular seminomas (8), myelomas
and other types of cancer (10), NEK2 is primarily
localized in the nucleus of neoplastic cells. We now
document that the nuclear localization of NEK2 is also
observed in several carcinomas and cancer cell lines in
which the kinase is upregulated. Thus, although our
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Figure 4. NEK2 phosphorylates SR proteins and modulates E1A splicing. (A) Western blot analysis of SR protein phosphorylation in HeLa cells
transfected with FLAG-SRPK1 or GFP-NEK2C using the anti-SR proteins 1H4 antibody. TUBULIN was detected as loading control.
(B) Schematic representation of the alternative splice variants of the E1A minigene. (C) RT-PCR analysis (upper panel) of the in vivo splicing
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analysis is too limited to draw conclusions, these results
suggest that nuclear localization of NEK2 is a common
feature of neoplastic cells.
The NEK2C splice variant was reported to localize
prevalently in the nucleus (22), suggesting that its selective
upregulation in cancer cells might account for the
observed localization of the kinase. However, our study
indicates that NEK2C is expressed at low levels in all
cancer cells analysed, raising doubts on its contribution
to the localization of NEK2 in primary tumours and in
cell lines. Conversely, upregulation of NEK2A, but not
NEK2B, is sufﬁcient to induce its nuclear localization,
suggesting that NEK2A is the prevalent isoform in the
nucleus of cancer cells.
Characterization of the subcellular distribution of
NEK2 pointed out its co-fractionation with several
splicing factors in the nuclear-insoluble material of cancer
cells. Moreover, NEK2 co-localized with two SR proteins
in nuclear splicing speckles. These inter-chromatin granules
are particularly enriched in SR proteins and are supposed
to function as nuclear storage sites for pre-mRNA process-
ing regulators (24). Assembly of splicing speckles and active
recruitment of SR proteins from these sites to the newly
synthesized pre-mRNA is strictly regulated by reversible
phosphorylation (34). Phosphorylation represents one of
the main mechanisms by which subtle regulation of the
splicing process, and especially of AS, is achieved (35,36).
These observations led us to hypothesize the existence
of a functional interaction between NEK2 and splicing.
Several results of our study support this hypothesis. First,
NEK2 interacts with and phosphorylates SRSF1. Second,
we found that the splicing activity of SRSF1 is modulated
by NEK2. Lastly, silencing of NEK2 negatively affects
AS events that are target of SRSF1 in live cells.
Collectively, these results point to NEK2 as a novel direct
regulator of SRSF1 phosphorylation and activity.
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The cellular localization and splicing activity of SRSF1
are regulated by reversible phosphorylation (26,37–39).
We observed that NEK2 did not inﬂuence the nuclear
localization of SRSF1 in HeLa and HEK293T cells
(Supplementary Figure S5). By contrast, our study
suggests that NEK2 can modulate SRSF1 splicing
activity similarly to SRPK1, the prototype member of
the SRPK family of kinases that mediate phosphorylation
of SR proteins (26). Overexpression of either NEK2 or
SRPK1 induced a similar pattern of SR proteins phos-
phorylation and caused a similar modulation of E1A
AS. Likewise, knockdown of NEK2 or SRPK1 similarly
reduced the splicing activity of SRSF1 toward the BCL-X
minigene. Although the effects of NEK2 might be indirect
(i.e. mediated by another kinase), three lines of evidence
support a direct action. First, our in vitro kinase assays
were performed using highly puriﬁed proteins, strongly
indicating that NEK2 can directly phosphorylate SRSF1
and SRSF7. Second, although NEK2 was recently
reported to induce activation of AKT in myeloma cells
(10), a signalling kinase known to directly and indirectly
modulate SR proteins phosphorylation (40,41), over-
expression or knockdown of NEK2 did not alter the
activity of AKT in HeLa cells (Supplementary Figure
S6). Third, the effect of NEK2 on BCL-X splicing was
not affected by knockdown of SRPK1. Thus, these experi-
ments suggest that NEK2 behaves as a bona ﬁde splicing
factor kinase in live cells.
Our study implicates NEK2 in AS regulation of several
SRSF1 target genes involved in cell viability. We found
that knockdown of NEK2 mimicked that of SRSF1, or
SRPK1, and induced expression of pro-apoptotic BCL-X,
BIN1 and MKNK2 splice variants. Consistently, NEK2
depletion sensitized HeLa cells to spontaneous and
stress-induced apoptosis, suggesting a pro-survival
function for this kinase. Although protection from cell
death may also involve other splicing-unrelated functions
of NEK2 (10), it is likely that enhanced splicing of the
anti-apoptotic variants of BCL-X, BIN1 and MKNK2
contributes to this pro-survival effect.
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As NEK2, SRPK1 is also overexpressed in human
cancers (42), suggesting that these kinases may act in
concert to modulate SRSF1 activity. In line with this hy-
pothesis, we found that NEK2 affected BCL-X splicing
independently of SRPK1. Thus, even if apparently redun-
dant, SRPK1 and NEK2 could regulate SR proteins phos-
phorylation and subsequent AS events in a coordinate
manner. In fact, the subcellular localization of SRPK1,
mainly cytosolic (17), and NEK2, predominantly nuclear
(this study), suggest a possible coordinated activity of
these kinases in different cellular compartments, as previ-
ously reported for SRPKs and CLKs (Cdc2-like kinases)
(43). Notably, activation of SRPK1 in response to AKT-
mediated signalling was reported to modulate gene expres-
sion by regulating AS programs (41). Because activation
of NEK2 by the ERK1/2 pathway was observed in germ
cells (44), and this pathway is often activated in cancer
cells, it is possible that NEK2 also participates to AS regu-
lation in response to environmental cues. Finally, as
NEK2 expression and activity peak during the late S-G2
phase (45), we cannot exclude the possibility that it could
affect SR protein function in a cell-cycle–dependent
manner, thus contributing to coordinate gene expression
regulation with cell cycle progression. Noteworthy,
another centrosomal kinase, AURKA, was shown to
modulate the apoptotic response to mitotic arrest of the
cell cycle by regulating the stability of SRSF1 (30).
In conclusion, our study identiﬁes NEK2 as a novel regu-
lator of AS, which promotes SRSF1-dependent splicing of
anti-apoptotic variants, thus contributing to cell survival.
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